ESR1 and breast carcinoma: Drugs such as selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) used for the treatment of ER+ breast carcinoma function by binding strongly to ER and limits the affinity of estrogen hormones for ER surface.